• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Blacksmith Medicines

  • January 8, 2021
  • New Biotech Startups

Blacksmith Medicines is using its purpose-built platform for metalloenzyme-targeted medicines to rationally design small molecule inhibitors for novel targets in immuno-oncology and inflammatory diseases. The company, which is a spin-out of Forge Therapeutics, was officially launched in early 2021 with seed funding and a research collaboration with Eli Lilly and Company.

Blacksmith Medicines’ platform is focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. The company says that more than 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes.

Blacksmith says its platform has several distinct advantages over traditional drug discovery approaches including:

  • A large proprietary fragment library of metal-binding pharmacophores (MBPs);
  • A comprehensive database containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease;
  • A first-of-its-kind metallo-CRISPR library of custom single guide RNAs;
  • An industry-leading metalloenzyme computational toolkit for docking, modeling and structure-based drug design; and
  • A robust and blocking intellectual property estate covering bioinorganic, medicinal, and computational chemistry approaches for metalloenzyme-targeted medicines.

Under the terms of the initial research collaboration agreement with Lilly, Blacksmith and Lilly will collaborate on up to five human metalloenzyme targets, with Blacksmith advancing novel small molecule inhibitors from fragment to ‘hit’ stage after which Lilly has the right to continue research, development, and commercialization. The overall agreement has a total potential deal size up to approximately $300 million.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.